These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26575506)

  • 1. Can Educational Interventions Improve Osteoporotic Women's Adherence to Treatment? A Literature Review.
    Alvaro R; DʼAgostino F; Cittadini N; Zannetti EB; Rao C; Feola M; Vellone E; Pennini A; Tarantino U
    Orthop Nurs; 2015; 34(6):340-53; quiz 354-5. PubMed ID: 26575506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture.
    White HJ; Bettiol SS; Perera R; Roberts NW; Javaid MK; Farmer AJ
    Fam Pract; 2010 Dec; 27(6):593-603. PubMed ID: 20693238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of factors affecting medication adherence among patients with osteoporosis.
    Yeam CT; Chia S; Tan HCC; Kwan YH; Fong W; Seng JJB
    Osteoporos Int; 2018 Dec; 29(12):2623-2637. PubMed ID: 30417253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.
    Hiligsmann M; Salas M; Hughes DA; Manias E; Gwadry-Sridhar FH; Linck P; Cowell W
    Osteoporos Int; 2013 Dec; 24(12):2907-18. PubMed ID: 23636230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How can the community pharmacist improve the adherence to anti-osteoporotic treatments].
    Duquet N
    J Pharm Belg; 2015 Sep; (3):4-13. PubMed ID: 26513831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis.
    Kothawala P; Badamgarav E; Ryu S; Miller RM; Halbert RJ
    Mayo Clin Proc; 2007 Dec; 82(12):1493-501. PubMed ID: 18053457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.
    Gleeson T; Iversen MD; Avorn J; Brookhart AM; Katz JN; Losina E; May F; Patrick AR; Shrank WH; Solomon DH
    Osteoporos Int; 2009 Dec; 20(12):2127-34. PubMed ID: 19499273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Patient Preferences for Osteoporosis Drug Treatment.
    Hiligsmann M; Bours SP; Boonen A
    Curr Rheumatol Rep; 2015 Sep; 17(9):61. PubMed ID: 26286178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
    Hiligsmann M; Boonen A; Rabenda V; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2012 Apr; 12(2):159-66. PubMed ID: 22458617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of adherence to medications for the treatment of osteoporosis.
    Gold DT; Silverman S
    Curr Osteoporos Rep; 2006 Mar; 4(1):21-7. PubMed ID: 16527004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations regarding adherence of anti-osteoporosis therapy.
    Lagari VS; McAninch E; Baim S
    Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and persistence: impact on outcomes and health care resources.
    Reginster JY
    Bone; 2006 Feb; 38(2 Suppl 2):S18-21. PubMed ID: 16443406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.